Mirikizumab-mrkz Injection shortage
To Be Discontinued 2 presentations · 1 manufacturers · first FDA posting 2025-12-22 · last update 2025-12-22
Manufacturers: Eli Lilly and Co.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27) | Eli Lilly and Co. | To Be Discontinued | — | A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain. | Posted 12/22/2025 Updated 12/22/2025 Discontinued 12/22/2025 |
| Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27) | Eli Lilly and Co. | To Be Discontinued | — | A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain. | Posted 12/22/2025 Updated 12/22/2025 Discontinued 12/22/2025 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)